NIBR Shanghai exits discovery to refocus on clinical development, local collaborations

Novartis AG doesn't have a better solution than its multnational peers for how to fruitfully leverage discovery science in China. The pharma is closing down discovery operations at its Shanghai-based Novartis Institutes for BioMedical Research (NIBR) in

Read the full 378 word article

User Sign In